Abstract: The present invention provides Thymic Stromal Lymphopoietin Receptor (TSLPR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TSLPR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TSLPR polypeptides.

Abstract: The present invention provides a method for protecting against or treating hearing loss in a subject. This method involves administering an effective amount of a protein tyrosine kinase inhibitor to the subject to protect against or to treat hearing loss.

Abstract: The present invention relates to methods of monitoring the menstrual cycle and/or the first half of pregnancy in a female by assessing the adhesion of lymphocytes from the female to uterine or lymphoid histological tissues from a pregnant animal or an animal that has been treated with gestational hormones. The method can be used to determine the ability of the lymphocyte donor's immune system to recognize and respond to an environment suitable for sustaining a pregnancy.

Abstract: Novel arabinopyranosyl nucleoside derivatives having the heterocyclic moiety and fluorine at the 2' position of the sugar ring (pyranose configuration), which have antitumor, antiviral and antimicrobial properties, are prepared by condensation of a pyrimidine, purine or 1,3-oxazine base with an acylated 2-deoxy-2,2-difluoro-D-arabinopyranoside and/or acylated 2-deoxy-2-bromo-2-fluoro-D-arabinopyranoside.

Abstract: A process for the large scale purification of human fibroblast interferon produced by human diploid fibroblasts under superinduction conditions characterized by a sequence of four chromatographic steps namely:(1) separation on CM-agarose;(2) separation on ConA-agarose;(3) separation on phenyl-agarose; and(4) elimination of ethylene glycol using CM-agarose which process yields a final overall recovery not less than 60% of the crude interferon starting material and having a specific activity not less than 1.times.10.sup.8 units per mg of protein.

Abstract: An improved assay procedure for quantitatively detecting LDH.sub.k isozyme in human serum is provided which utilizes previously known electrophoretic gel separation procedures combined with an improved staining method wherein the staining solution has a constant temperature of about 37.degree. C. and a pH of about 8.0, and is contacted with the gel matrix for at least 3 hours in the absence of oxygen and light. This improved assay procedure may be used as an adjunct to other procedures for diagnosing the presence of primary cancer, as a post-operative indicator of metastatic cancer and in monitoring the success of cancer therapy.

Abstract: This invention relates to cytotoxic compounds. More particularly, this invention relates to conjugates of antitumor agents, and thiophospholipids exhibiting enhanced antitumor activity to methods for producing such compounds and to pharmaceutical compositions containing cytotoxically effective amounts of such compounds as a primary effective ingredient.